Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas Vows Intensive Investment in 6 Late-Stage Assets to Weather Patent Cliff: CEO
April 27, 2018
- Torii Calls Off PII Study of Menlo’s Pruritus Candidate
April 27, 2018
- Ono Files Metyrosine in Japan
April 27, 2018
- Chugai Seeks Japan OK for Hemlibra in Non-Inhibitor Carriers, New Dosing
April 27, 2018
- Bayer Japan Chief “Disappointed” at PMP Removal for Xarelto, Shows Eagerness for Add’l Indications
April 27, 2018
- Astellas Sales Drop 0.9% due to LLP Sell-Off, Japan Biz Hit by Generic Entry
April 27, 2018
- Otsuka’s Jynarque Earns FDA Nod for ADPKD at Second Attempt
April 26, 2018
- Encorafenib/Binimetinib Combo Filed in Japan: Ono
April 26, 2018
- Jitsubo Aims to Enter Contract-Manufacturing Business for Peptide Drug Substances
April 25, 2018
- Gilteritinib Filed in Japan, US for AML: Astellas
April 25, 2018
- Takeda, Shire Reach Preliminary Deal, Extend Takeover Deadline to May 8
April 25, 2018
- Takeda Makes Fifth Pitch for Shire Buyout as Deadline Looms
April 25, 2018
- Shionogi to Transfer Manufacturing Functions to Dedicated Unit
April 24, 2018
- Eisai Transfers European Prialt Rights to Riemser
April 24, 2018
- Top Court Favors Sandoz in Elplat Patent Suit
April 24, 2018
- Atozet, Zetia-Lipitor Combo, Now Available in Japan after Delay
April 24, 2018
- Dupixent Hits Japan Shelves: Sanofi
April 24, 2018
- Novartis Seeks Japan Approval for Kymriah, Will Outcome-Based Model Be Put in Place?
April 24, 2018
- Japan Ethical Drug Sales in 54 Fields Shrink 1.6% in 2017
April 23, 2018
- Takeda Sweetens Bid for Shire, Ups Cash Component
April 23, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…